S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
Susan O'Brien,Francis J. Giles,Moshe Talpaz,Jorge E. Cortes,Mary Beth Rios,Jianqin Shan,Deborah A. Thomas,Michael Andreeff,Steven M. Kornblau,Stefan Faderl,Guillermo Garcia-Manero,Kevin P. White,Susie Mallard,Emil J. Freireich,Hagop M. Kantarjian +14 more
TL;DR: The goals of the current study were to evaluate the efficacy of the triple combination regimen with IFN‐α, ara‐C, and HHT in newly diagnosed Ph‐positive CML and to assess the impact of the added sequential therapy with imatinib on overall prognosis.
Journal ArticleDOI
Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy.
Stefan Faderl,Deborah A. Thomas,Susan O'Brien,Farhad Ravandi,Guillermo Garcia-Manero,Gautam Borthakur,Alessandra Ferrajoli,Srdan Verstovsek,Mohamed Ayoubi,Michael Rytting,Jennie Feliu,Hagop M. Kantarjian +11 more
TL;DR: An augmented version of hyper-CVAD with intensified doses of vincristine, dexamethasone, and asparaginase is designed and found to be suitable to be studied in younger adults with untreated ALL.
Journal ArticleDOI
Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome
Azra Raza,Azra Raza,Naomi Galili,Natalie S. Callander,Leonel Ochoa,Lawrence Piro,Peter D. Emanuel,Stephanie F. Williams,Howard A. Burris,Stefan Faderl,Zeev Estrov,Peter T. Curtin,Richard A. Larson,James G. Keck,Marsha Jones,Lisa Meng,Gail L. Brown +16 more
TL;DR: Phase 2 studies of ezatiostat hydrochloride liposomes for injection in MDS are supported by the tolerability and HI responses observed.
Journal ArticleDOI
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
Stefan Faderl,Farhad Ravandi,Xuelin Huang,Xuemei Wang,Elias Jabbour,Guillermo Garcia-Manero,Tapan M. Kadia,Alessandra Ferrajoli,Marina Konopleva,Gautam Borthakur,Jan A. Burger,Jennie Feliu,Hagop M. Kantarjian +12 more
TL;DR: In this paper, a combination of clofarabine plus low-dose cytarabine followed by a prolonged consolidation alternating with decitabine was designed for older patients with acute myeloid leukemia (AML).
Journal ArticleDOI
Phase II Study of Alemtuzumab in Combination With Pentostatin in Patients With T-Cell Neoplasms
Farhad Ravandi,Ahmed Aribi,Susan O'Brien,Stefan Faderl,Dan Jones,Alessandra Ferrajoli,Xuelin Huang,Sergernne York,Sherry Pierce,William G. Wierda,Dimitrios P. Kontoyiannis,Srdan Verstovsek,Barbara Pro,Luis Fayad,Michael J. Keating,Hagop M. Kantarjian +15 more
TL;DR: The combination of alemtuzumab and pentostatin is feasible and effective in T-cell neoplasms and infections, including cytomegalovirus reactivation, are a concern, they may be minimized with adequate prophylactic antibiotic therapy.